A recent report published by Infinium Global Research on the gastric
cancer drugs market provides an in-depth analysis of segments and sub-segments in
global as well as regional gastric cancer drugs market. The study also
highlights the impact of drivers, restraints and macro indicators on the global
and regional gastric cancer drugs market over the short term as well as long
term. The report is a comprehensive presentation of trends, forecast and dollar
values of the global gastric cancer drugs market. According to the report the global
gastric cancer drug market is projected to grow at a CAGR of 9.5% over the
forecast period of 2018-2024.
The report on the global gastric cancer drugs market covers segments
such as route of administration, lines of chemotherapy and molecule type. Based on the route of administration the global gastric cancer drugs market is
categorized into oral and parenteral. Based on lines of chemotherapy the
global gastric cancer drugs market is categorized into first-line chemotherapy
and second-line chemotherapy. Based on the molecule type, the global gastric
cancer drug market is categorized into small molecules and biologics.
The report provides regional analysis covering geographies such as
North America, Europe, Asia-Pacific, and Rest of the World. In this section, the
key trends and market size for each geography are provided for 2016-2024.
The countries covered in the North America region include the U.S., Canada, and
Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia,
and others. Moreover, Germany, U.K., France, Spain, and Rest of Europe
are included in the European region. The U.S. drives the growth in the North
America region is the largest market in the region. The Asia-pacific region offers a substantial potential for market growth owing to rapid
growth in markets such as India and China.
The APAC region is projected to experience growth at a CAGR of x.x%
The report provides profiles of the companies in the global
gastric cancer drugs market such as Amgen, AROG Pharmaceuticals, Ipsen
Biopharmaceuticals, Array Biopharma, Taiho Oncology, AstraZeneca, ARIAD
Pharmaceuticals, Eli Lilly, Galena Biopharma and ASLAN Pharmaceuticals.
The report provides deep insights on demand forecasts, market
trends, and micro and macro indicators. Also, this report provides
insights into the factors that are driving and restraining the global gastric
cancer drug market. Moreover, the IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of gastric cancer
drugs market. Moreover, the study highlights current market trends and provides
forecast from 2018-2024. We also have highlighted future trends in the gastric
cancer drugs market that will impact the demand during the forecast period.
Moreover, the competitive analysis given in each regional market brings an
insight on the market share of the leading players. This report will help
manufacturers, suppliers, and distributors of the gastric cancer drugs market to
understand the present and future trends in this market and formulate their